Almirall investor relations. The data provided is for informational purposes only.

Almirall investor relations Jul 22, 2024 · Almirall (total revenue in 2023: €898. 4% 17. com Phone: (+34) 600 430 581 Phone: (+34) 93 291 3087 Corporate Communications contact Almirall Mar Ramírez mar. and Subsidiaries (Almirall Group) Consolidated Financial Statements for the year ending on 31 December 2022, prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union (Translation of a report originally issued in Spanish. . (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, today announced the launch of a non pre-emptive share capital increase (the “Capital Increase”) for a total aggregate amount (including nominal value and share issue premium) of approximately EUR 200,000,000 by issuing new ordinary shares of the Company Jun 13, 2023 · Barcelona, Spain. Subscribe here. Zipcode：210042. Dec 5, 2024 · From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. H1 2024 Financial Results – 22nd July 2024 Q3 2024 Financial Results – 11th November 2024. com Transfer of global rights for Eklira and Duaklir to Covis Pharma completed Media contact Almirall: Investors’ Relations contact Tinkle Almirall Laura Blázquez Pablo Divasson del Fraile lblazquez@tinkle. Lebrikizumab (EBGLYSS) is ranked as the number one interleukin inhibitor for severe atopic dermatitis (AD) in adults and adolescents on TNF BIO 2406b from May 1, 2024. Key highlights Total Revenues (€ Million) R&D Social Number of employees 1,765 Woman: 944 | Men: 821 Environment CO 2 emissions 12,877 (-11% vs 2018) 2 3 908. com Phone: (+34) 659 614 173 Legal warning Dec 19, 2023 · Furthermore, Almirall’s executive team will host one-on-one investor and business development meetings in San Francisco during the same period as the annual J. ramirez@almirall. Net Sales increased by 6. com Phone : (+34) 671 580 492 Pablo Divasson del Fraile Head of Investor Relations pablo. The data provided is for informational purposes only. 25%) Media; Discover insights from Almirall's annual reports and investor relations material with Quarterlytics' easy-to-use platform. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. T Jul 22, 2024 · Almirall (total revenue in 2023: €898. Almirall, S. ramí [email protected] Phone: (+34) 600 430 581: Phone: (+34) 93 291 30 87: Phone: (+34) 659 614 173 Jul 24, 2023 · Investors’ Relations Almirall Pablo Divasson del Fraile pablo. The transaction has been closed for an upfront payment of €45MM. Find and download the Almirall financial information. Full year 2021 Financial Results – February 22nd, 2022. com Phone: (+34) 600 430 581 Phone: (+34) 93 291 3087 Corporate Communications contact: Almirall Mar Ramírez Oct 31, 2020 · For more information, please visit almirall. sagaert@etherna. ramirez@almirall Nov 14, 2023 · Almirall Investors’ Relations contact: Almirall Corporate Communications contact: Tinkle: Almirall: Almirall: Laura Blázquez: Pablo Divasson del Fraile: Mar Ramírez [email protected] [email protected] mar. com Phone: (+34 Feb 19, 2024 · ALM). 4 811. General Media enquiries. Morgan Healthcare Conference 2025 (audio) MP3 (15. com Phone: (+34) 600 430 581 Phone: (+34) 93 291 3087 Corporate Communications contact: Almirall Mar Ramírez mar. P Jul 22, 2024 · BARCELONA, Spain, July 22, 2024--Almirall, S. As a result of Almirall's decision to exercise its option, the company will pay Dermira $50 MM and Dermira will be eligible to receive In accordance with Securities Markets Law, Almirall S. 43rd Annual J. com investors@almirall. 0 755. 5 116. €119. S. Nov 14, 2023 · BARCELONA, Spain and VANCOUVER, (WA), USA. ramírez@almirall. 4 10. Jul 22, 2024 · BARCELONA, Spain, July 22, 2024 -- (BUSINESS WIRE)-- Almirall, S. ramirez@almirall Phone: (+34) 659 614 173 Almirall Investors’ relations contact: Pablo Divasson del Fraile pablo. be Corporate communications: media May 13, 2024 · Almirall, S. Media contact Almirall: Investors’ Relations contact Tinkle Almirall Laura Blázquez Pablo Divasson del Fraile lblazquez@tinkle. Nov 11, 2024 · Almirall continued to deliver strong sales growth in the first nine months of 2024 which were driven by the dermatology business, and especially the biologics portfolio in Europe. About Almirall Almirall is a global pharmaceutical company dedicated to medical dermatology. Address: 699-18 Xuanwu Avenue Nanjing China. Almirall is a global biopharmaceutical company focused on skin health. Yours sincerely, Pablo Divasson del Fraile Investor Relations Department investors@almirall. FY 2020 Financial Results – 22nd February 2021; Q1 2021 Financial Results – 10th May 2021; H1 2021 Financial Results – 26th July 2021; 9M 2021 Financial Results – 8th November 2021 . Corporate Communications: Investor Relations Feb 20, 2023 · Investor Calendar 2023. Maria Duro Head of External Communications maria. T + 34 932 91 30 00. 4 MM, EBITDA was €52. For more information, please visit almirall. com Tel. Q1 2023 Financial Results – 8th May 2023. If you experience any issues with this process, please contact us for further assistance. ramirez@almirall Phone: (+34) 659 614 173 Almirall Investors’ relations contact: pablo. ISS is a global leader in Integrated Facility Services, offering a compelling combination of market leadership, stable profitability, and robust cash flow generation. Our events offer investors the opportunity to meet our management and investor-relations team and learn more about our strategy. eu Phone: (+44) 7711 821527 Investor relations contact: Bernard. 9M 2023 Financial Results – 13th November 2023. (ALM) Investor Relations material, such as Live Earnings Calls, Transcripts, Slides, Reports, and Estimates using Quartr Jun 10, 2024 · Corporate Communications: Investor Relations corporate. - Almirall has appointed Jordi Molina Alsina as manager of the Investor Relations Department. This document includes only summary information and does not intend to be comprehensive. Corporate Communications: Investor Relations Oct 15, 2024 · BARCELONA, Spain. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023. Almirall’s Nine-month 2024 Results: Almirall reports strong performance at Q3 2024 - driven by successful commercial execution of the dermatology portfolio, fuelled by biologics growth Almirall, S. com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, Almirall and Dermira previously entered into an option and license agreement in February 2019 pursuant to which Almirall was granted this exclusive option in exchange for an upfront option fee of $30 MM. com and the complete recording will be available today on the same webpage. May 8, 2023 · Investors’ Relations Almirall Pablo Divasson del Fraile pablo. Almirall is a global pharmaceutical company dedicated to medical dermatology. 8 2019 2018 €92. 5 million euros. 5 MM (+4% y-o-y) with total EBITDA of €174. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non pre-emptive share capital increase announced yesterday evening (the “Capital Increase”) following completion of the accelerated book-building offering, which was carried out by J. July 1, 2021 – Almirall S. com Phone: (+34) 659 614 173 Phone: (+34) 93 291 30 87 May 13, 2024 · Almirall delivered strong sales growth in the first quarter of 2024 which continues to be driven by the dermatology business in Europe. com), including Sep 25, 2024 · Corporate Communications: Investor Relations corporate. Investor Relations. • The financial result decreased to a negative result of €16. Feb 19, 2024 · Investor Calendar 2024. com Phone: (+34) 600 430 581 Phone: (+34) 93 291 30 87 Corporate Communications contact: Almirall Mar Ramírez Mar. Barcelona, Spain Almirall’s Ilumetri® (tildrakizumab) demonstrates high rates of skin clearance and sustained wellbeing restoration in Adults with Moderate-to-Severe Plaque Psoriasis to general population levels for up to one year1 Media contact Almirall: Investors’ Relations contact Tinkle Almirall Laura Blázquez Pablo Divasson del Fraile lblazquez@tinkle. ramí [email protected] Phone: (+34) 600 430 581: Phone: (+34) 93 291 30 87: Phone: (+34) 659 614 173 Media contact Almirall Investors’ Relations contact Tinkle Almirall Sergi García Valero Pablo Divasson del Fraile sgarcia@tinkle. com Phone: (+34) 600 430 581 Phone: (+34) 93 291 3087 Corporate Communications contact: Almirall Ester Riu ester. This position was created after announcing 20 June as the proposed date for the company listing. We collaborate with scientists and healthcare professionals to address patient needs through science to improve their lives. 4MB) 43rd Annual J. com Media contact Almirall Investors’ Relations contact Tinkle Almirall Laura Blázquez Pablo Divasson del Fraile laura. com Media contact Almirall Investors’ Relations contact Tinkle Almirall Laura Blázquez Pablo Divasson del Fraile lblazquez@tinkle. 5 million due to the adjustment of the fair value of the equity To request more information about Almirall, you have a form and phone number. 5%. +34 93 291 30 00 Fax +34 93 291 31 80 Solutions with you in mind www. launch of Klisyri marks another important milestone for Almirall toward our goal to be a leader in the field of dermatology and deliver new, innovative and effective treatment options,” said Pablo Alvarez, President and General Manager of Almirall U. Senior Manager, Investor Relations +33 6 52 19 98 92; IPN price. corporate. Access Almirall S. as explained in Note 8 of the accompanyig Financial Statements. Almirall is a global biopharmaceutical company focused on medical dermatology. Almirall launches Almirall Innovation Hub The Hive, creating a novel collaborative innovation hub to advance life sciences and healthcare. This document may not be disclosed or published or used by any person or entity for any reason without the prior, express written Jul 25, 2022 · Investor Calendar 2022 • 9M 2022 Financial Results – 10th November 2022. Almirall’s Nine-month 2024 Results: Almirall reports strong performance at Q3 2024 - driven by successful commercial execution of the dermatology portfolio, fuelled by biologics growth 4 days ago · You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. T+ 34 932 913 000. For more information, please visit www. Q1 2023 Financial Results – 8th May 2023 H1 2023 Financial Results – 24th July 2023 9M 2023 Financial Results – 13th November 2023 About Almirall. Fax：025-85471729 Investors and others should note that we routinely communicate with investors and the public using our website (www. 30 (-0. H1 2023 Financial Results – 24 th July 2023. Please consult this section for comprehensive details on share performance and other financial matters. INTERNAL USE Financial Results & Business Update Q1 2024 Total Income Statement cash collection will be recognised in the coming years. com Corporate Communications contact Almirall: Investors’ Relations contact Corporate communications team Pablo Divasson del Fraile About us. Additionally, the FDA has patients 12 years of age and older with moderate-to-severe AD. (LBTSF) Q2 2023 Earnings Call Transcript. (NYSE: EGP), a member of the S&P Mid-Cap 400 and Russell 2000 Indexes, is a self-administered equity real estate investment trust focused on the development, acquisition and operation of industrial properties in major Sunbelt markets throughout the United States with an emphasis in the states of Texas, Florida, California, Arizona and North Carolina. Please find below the Financial Calendar 2023. 5 MM (increase of 1. Share Performance; Almirall Media Relations. May 8, 2023 · Investor calendar 2023. Find out what drives us to do what we care about every day. es Phone: (+34) 93 93 545 0861 Almirall Corporate Communications contact: Mar Ramírez mar. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. This document may not be disclosed or published or used by any person or entity for any reason without the prior, express written For more information, please visit www. About Almirall . (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of fungal infection of the nail, known as onychomycosis, under the trade name of Jublia ®. com Media contact: Investors’ Relations contact Tinkle Almirall Pilar Colomer Pablo Divasson del Fraile pcolomer@tinkle. and Subsidiaries (Almirall Group) Notes to the Consolidated Financial Statements for the year ending on 31 December 2022 (Thousands of euros) 7 1. 8 MM, 1900 employees globally) has direct presence in 21 countries and marketed products in over 100. May 1, 2024 · Norway is the first country in the Nordic region where lebrikizumab will be available as a prescription medicine. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. This document has been prepared by Almirall, S. October 28th, 2024 – Almirall, a global pharmaceutical company dedicated to medical dermatology, successfully hosted ImmunoSkin, its annual scientific conference focused on chronic inflammatory skin conditions This year’s event, held from October 26 to 27, brought together leading international experts to discuss the latest sc ientific advancements and innovative Nov 11, 2024 · corporate. Almirall will continue to receive Royalties from the agreement initially signed with AstraZeneca. investors@almirall. Activity of the Group Almirall, S. (BME: ALM), a global biopharmaceutical company focused on skin health, and Kaken Pharmaceutical (KKPCF) announced today that the companies have entered into a license and distribution agreement in which Kaken Pharmaceutical grants Almirall the exclusive right for the development and commercialization of the topical formulation of efinaconazole in Feb 18, 2021 · “The U. Information. com Phone: (+34) 93 545 12 51 Phone: (+34) 93 291 3087 Corporate Communications contact: Almirall Maria Duro maria. Almirall (total revenue in 2023: €898. (the “Company”) exclusively for use during the presentation. This section is dedicated to providing useful and detailed information for our shareholders and investors in accordance with current legislation. Please fulfill the form to receive mail alerting of our news releases and publications Share performance. For more information and to schedule an investor or business development meeting, please contact Pablo Divasson del Fraile, at pablo. Almirall continued The event will be live streamed at www. com Phone: (+34) 659 614 173 Phone: (+34) 93 291 30 87 Sep 13, 2024 · Almirall (total revenue in 2023: €898. com Phone: (+34) 659 61 41 73 Legal warning Feb 19, 2024 · Almirall’s Net sales reached €894. : (+34) 932 913 087 Media contact Almirall Investors’ Relations contact Tinkle Almirall Laura Blázquez Pablo Divasson del Fraile lblazquez@tinkle. 1 MM in 2023 (-12. Carlos Gallardo joined the pharmaceutical industry over 20 years ago when he joined Pfizer based in New York. (ALM) announced today that the U. 2% y-o-y), mainly due to decreased contributions from other income following last year's Total Almirall Derma* 128. Almirall’s Nine-month 2024 Results: Almirall reports strong performance at Q3 2024 - driven by successful commercial execution of the dermatology portfolio, fuelled by biologics growth Feb 18, 2021 · “The U. and Subsidiaries (Almirall Group) Notes to the Consolidated Financial Statements for the year ending on 31 December 2021 (Thousands of euros) 7 1. com Phone: (+34) 659 61 41 73 Legal warning Identifiers like your name, address, telephone number, and e-mail address, (“Personal Information”), such as when you report an adverse event, ask for information on our products, subscribe to our email alerts, ask for information regarding media or investors relations, give us feedback, express interest in our events or otherwise Almirall Investors’ Relations contact: Almirall Corporate Communications contact: Tinkle: Almirall: Almirall: Laura Blázquez: Pablo Divasson del Fraile: Mar Ramírez [email protected] [email protected] mar. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. com Phone: (+34) 659 614 173 Phone: (+34) 93 291 30 87 May 4, 2023 · Investor Relations Department inversores@almirall. riu@almirall. duro@almirall. Receive Almirall financial information delivered to your mail. Follow us. P. Sign up now! Media contact Almirall Investors’ Relations contact Tinkle Almirall Laura Blázquez Pablo Divasson del Fraile lblazquez@tinkle. es pablo. Almirall's annual report reflects our financial and commercial performance during the year, as well as our commitment to society and health. Almirall the opportunity to reinforce its neurology business unit in Spain. (“Almirall”) announces the following: Almirall and EpimAb Biotherapeutics today announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs. Phone: (+34) 673053767 Almirall Media Relations. , Suite 400 in Malvern, PA 19355. com Phone: (+34) 600 430 581 Phone: (+34) 93 291 30 87 Corporate Communications contact Almirall Mar Ramírez mar. 2 MM For media and investors only Issued: June 28, 2024. 8 MM, 1900 employees globally) has a direct presence in 21 countries and affiliates in over 70 others. (“ALM”), in accordance with the Spanish Securities Markets Law, notifies the following: Almirall announced today the following update to the late stage pipeline: Lebrikizumab - atopic dermatitis On the 9th of October the Phase 3 program for Lebrikizumab was initiated. Sincerely, Pablo Divasson del Fraile Investor Relations Department investors@almirall. We are dedicated to providing investors with the tools they need to understand our company and goals. com Almirall Corporate Communications contact: Mar Ramírez mar. Created with sketchtool. About Almirall. com Phone: (+34) 600 430 581 Phone: (+34) 93 291 30 87 Corporate Communications contact Almirall Mar Ramírez For more information, please visit almirall. com Almirall], has waived 8 free-of-charge allocation rights, corresponding to 8 Almirall shares held by it. com Phone: (+34) 93 291 3087 Corporate Communications: Almirall Mar Ramírez mar. Feb 21, 2022 · Investor Calendar 2021 Q1 2022 Financial Results – 9th May 2022 H1 2022 Financial Results – 25th July 2022 9M 2022 Financial Results – 14th November 2022. com Solutions with you in mind Annual Report 2007 Annual Report 2007 Almirall COBERTES_OK_2 ING. Under the terms of this agreement, Read and listen to Almirall, S. 40 €-0. November 14th, 2023 – Almirall S. Investors. Our global presence. “Atopic dermatitis is a chronic skin condition that can be challenging to manage and can have a significant impact on the person's quality of life. com Media contact: Tinkle Pilar Colomer pcolomer@tinkle. com Dec 21, 2021 · Throughout its 78-year history, Almirall has retained a strong focus on the needs of patients. com Presentation of Q3 2022 Financial Results: Information on stock, financials, earnings, subsidiaries, investors, and executives for Almirall. Phone: (+34) 659 614 173 Nov 14, 2023 · Investors and others should note that we routinely communicate with investors and the public using our website (www. Get all the information. com Phone: (+34) 659 61 41 73 Legal warning Dec 12, 2023 · Media contact etherna: RHA Communications Richard Hayhurst richard@rhacomms. Identify trends, assess risk, and make informed investment decisions. com Phone: (+34) 659 614 173 Phone: (+34) 93 291 30 87 May 28, 2024 · Almirall (total revenue in 2023: €898. Oct 10, 2023 · RIJSWIJK, the Netherlands and BARCELONA, Spain. We would like to show you a description here but the site won’t allow us. The program includes Alibaba Investor Relations site contains information about Alibaba Corporation Inc and provides information about the business & financial information relevant to shareholders, potential investors, and financial analysts. Apr 24, 2024 · Vice President, Investor Relations +41 795728712; Nicolas Bogler. This section includes the financial reports issued by the company to the National Securities Market Commission (CNMV) in PDF format. INTERNAL USE Financial Results & Business Update Q1 2023 highlights Good start to the year, European dermatology showing strong growth 5 * Wynzora® is authorized in France, UK, Spain, Czech Republic, Denmark, Norway, Sweden, Finland, Germany, Portugal, Italy, Ireland, Investors Relations. Mr. , through the bodies and departments of the Company and especially through the Investors Relations Department, establishes and implements this Policy for communication and contact with shareholders, institutional investors and proxy advisors in Laboratorios Almirall, S. Sep 29, 2022 · Telephone: 025-85566666 Fax：025-85262330. com Phone: (+34) 627 377 980 Phone: (+34) 93 291 30 87 Corporate Communications contact Almirall Mar Ramírez mar. divasson@almirall. absci. “We are committed to providing patients with affordable access to our Almirall, S. com Phone: (+34) 93 291 3087 Legal warning This document includes only summary information and is not intended to be exhaustive. October 15, 2024 – Almirall, S. Oct 28, 2024 · BARCELONA, Spain. Jun 12, 2023 · Barcelona, Spain. blazquez@tinkle. 4% YoY) driven by higher sales growth, with a gross margin of 63. com Phone For more information, please visit almirall. Morgan Healthcare Conference, running from 8 th to 11 th January, 2024. 13 June 2023 — Almirall S. com Phone: (+34) 659 614 173 Investor Calendar 2024. is the Parent Company of a Group of companies (hereinafter, the Almirall Group), which Dec 30, 2024 · Almirall, S. Investor Relations Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. com This document has been prepared by Almirall, S. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. communication@almirall. qxd:Maquetación 1 24/4/08 19:25 Página 1 May 10, 2021 · Investor Calendar 2021. 1,2 Jul 2, 2024 · Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 – reduce absolute direct greenhouse gas emissions by 50%, minimize the gender pay gap and extend its patient-centric approach Almirall’s sustainability achievements have been recognized Jul 1, 2021 · BARCELONA, Spain. com Corporate Communications: Investor Relations Apr 7, 2020 · Almirall announced a webcast presentation and a conference call to detail the acquisition of Aqua Pharmaceuticals Investors Relations. and Subsidiaries (Almirall Group) CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS AS AT 30 JUNE 2022 and 31 DECEMBER 2021 (Thousands of Euros) 2 ASSETS Note 30/06/2022 31/12/2021 Unaudited Audited Goodwill 8 315,966 315,966 Intangible assets 9 920,429 916,056 Right-of-use assets 10 20,235 20,033 Nov 9, 2020 · Investor Calendar 2021. Corporate Communications: Investor Relations. General Mitre, 151 08022 Barcelona Spain Tel. com Media contact Almirall: Investors’ Relations contact Tinkle Almirall Laura Blázquez Pablo Divasson del Fraile lblazquez@tinkle. Our noble purpose guides our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. Find out the latest about Almirall at our social networks. For general information, contact us by phone at (610) 644-7000 or fax at (610) 644-1985 Monday – Friday from 8am to 5pm. Our extensive product portfolio is available in more than 100 countries – either through the 15 affiliates or via the network of strategic partnerships that we have developed over time. Q1 2024 Financial Results – 13th May 2024; H1 2024 Financial Results – 22nd July 2024; 9M 2024 Financial Results – 11th November 2024; About Almirall. 11 November 2024. In the event of discrepancy, Here, we provide corporate presentations submitted to the analyst and investors community. com May 13, 2024 · Back to newsroom Almirall’s Q1 2024 Results: Almirall delivers strong start of 2024 – Q1 net. Nov 11, 2024 · Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth Why invest in ISS. is the parent company of a Group of companies (hereinafter, the Almirall Group), which is Feb 21, 2022 · Investors Relations. Expertise in the areas of investor relations, analyst, corporate development, corporate comms and strategy. This agreement also contemplates potential milestones up to €15MM. Morgan Healthcare Conference 2025 PDF (1. 7MB) Dec 19, 2023 · Investors Relations. divasson Almirall S. First as an executive in different countries and positions ranging from Strategy, Sales, Licensing, M&A and to Country Management. Almirall and partner Eli Lilly and Company expect regulatory decisions in the European Union and U. com Corporate Communications: Investor Relations Investors Relations. H1 2021 Financial Results – 26th July 2021; About Almirall . Currently at Almirall: Investor relations Analysts relations Rating agencies ESG JORDI MOLINA ALSINA, INVESTOR RELATIONS MANAGER AT ALMIRALL Barcelona, 7 June 2007. A. Nov 9, 2023 · INTERNAL USE Financial Results & Business Update 9M 2023 highlights Solid performance, modestly raising FY 2023 Net Sales guidance 5 * Wynzora® is authorized in France, UK, Spain, Czech Republic, Denmark, Norway, Sweden, Finland, Germany, Portugal, Italy, Ireland, Netherlands & Austria under a different tradename: Winxory. : (+34) 932 913 087 accompanying income statement includes mainly, the impairments of the participation in Almirall, Inc. com Phone: (+34) 93 291 3087 Corporate Communications contact: Almirall Mar Ramírez mar. later this year. com Phone: (+34) 659 614 173 Almirall Investors’ relations contact: Pablo Divasson del Fraile pablo. Thank you for your interest. com) and our investor relations website (investors. com Phone: (+34) 600 430 581 Phone: (+34) 93 291 30 87 Corporate Communications contact Almirall Mar Ramírez The information contained on the following pages of the website is restricted and is not for distribution in or into or to any person located or resident in the United States, its territories and possessions (including Puerto Rico, the U. com. (ALM) earnings call transcripts and investor relations material. Almirall is a leading skin-health focused global pharmaceutical company based in Barcelona that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands), any state of the United States and the District of Columbia (the Investor Calendar 2021. Molina’s main mission is to liaise Almirall is a global biopharmaceutical company focused on skin health. 9M 2023 Financial Results – 13 th November 2023. com Phone: (+34) 600 430 581 Phone: (+34) 93 291 3087 Corporate Communications contact Almirall Mar Ramírez ALMIRALL ANNOUNCES Almirall, S. is located at 101 Lindenwood Dr. May 13, 2024 · Investor calendar 2024. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, today announced an agreement with Centrient Pharmaceuticals (‘Centrient’), a global business-to-business pioneer in sustainable, biosynthetic pharmaceutical products, including antibiotics, next-generation statins, and anti-fungals Jun 10, 2024 · Corporate Communications: Investor Relations corporate. Dec 2, 2024 · EastGroup Properties, Inc. to send you the requested Investor Email Alert updates. com Phone: (+34) 659 614 173 About Microsoft Feb 20, 2023 · Investor Calendar 2023. 659 614 173 Investors’ Relations Almirall Pablo Divasson del Fraile pablo. Total revenues in 2020 were 814. The official documents, including the FEUE format, can be accessed on the CNMV website: Interim financial reports; Annual financial reports Almirall delivered strong sales growth in the first quarter of 2024 which continues to be driven by the dermatology business in Europe. com Phone: (+34 Nov 9, 2023 · Almirall, S. Food and Drug Administration (FDA) has completed its filing review and determined that the New Drug Application (NDA) for tirbanibulin, also known as ALM147891, for the treatment of actinic keratosis (AK), is sufficiently complete to permit a substantive review. By providing your email address below, you are providing consent to Walmart Inc. Use the PitchBook Platform to explore the full profile. H1 2023 Financial Results – 24th July 2023. com Phone: (+34) 659 614 173 Legal warning Jul 22, 2024 · Investor events. com Almirall Corporate Communications contact: Mar Ramírez Pablo Divasson del Fraile mar. In 2004, he joined Almirall where he has remained until the present day. 12 June 2023 — Almirall S. , the global pharmaceutical company based in Barcelona, and Bicosome, a start-up company that develops and commercializes high performance cosmetic and dermopharmaceutical ingredients, announced that they have entered into a research, collaboration and sublicense agreement for the development of multiple topical dermatological products, based upon Bicosome's proprietary patented Almirall, LLC – U. Feb 20, 2023 · Investor Calendar 2023. Oct 29, 2024 · Corporate Communications: Investor Relations corporate. com Phone: (+34) 671 580 438 institutional investors and proxy advisors The Board of Directors of Almirall, S. October 10th 2023 - Almirall S. We are where you need us to be. com Phone: (+34) 659614173 Legal warning Nov 10, 2022 · Investors’ Relations contact Almirall Pablo Divasson del Fraile pablo. almirall. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Full year 2023 Financial Results - February 19th, 2024; Q1 2024 Financial Results - 13th May, 2024; H1 2024 Financial Results - 22nd July, 2024; 9M 2024 Financial Results - 11th November, 2024; About Almirall. (OTCPK:LBTSF) Q2 2023 Earnings Conference Call July 24, 2023 4:00 AM ET Company Participants Pablo Divasson - Director of Investor Relations and Corporate Communications Carlos Gallardo Dec 11, 2017 · Almirall and Athenex have entered into a strategic partnership to develop and commercialize KX2-391 in the United States and Europe; KX2-391 is a first-in-class topical treatment currently in Almirall launches The Hive, creating a novel collaborative innovation hub to advance life sciences and healthcare. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell Almirall launches Almirall Innovation Hub The Hive, creating a novel collaborative innovation hub to advance life sciences and healthcare. 6% to a total of €247. 4 MM The individual meetings will take place at the same time as the annual JP Morgan Healthcare Conference. cwjy gsqusu fduyrb lwxawunl dxrjwp qezos hiix fqad klsj ruaxv